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Abstract
Background: Pediatric onset of systemic lupus erythematosus (SLE) is associated with major organ involvement,
and African patients tend to develop more aggressive disease than patients of European descent. Although
cardiovascular involvement is common in pediatric SLE, there are few published reports on the subject. This study
describes the frequency and characteristics of cardiac and vascular manifestations of pediatric SLE in a multi-ethnic
South African cohort.
Methods: Demographic, clinical, and echocardiographic data were collected from pediatric SLE patients at two
centers in Cape Town, South Africa. At the time of investigation, this cohort consisted of 93 participants diagnosed
with SLE according to international classification criteria prior to the age of 19. Individuals with cardiac and/or
vascular involvement were identified by retrospective chart review. Cardiac manifestations were defined as
presence of pericardial effusion, myocarditis, cardiomyopathy, cardiac failure, Libman-Sacks endocarditis, myocardial
infarction, and arrhythmia. Vascular manifestations included deep vein thrombosis, pulmonary embolism, sinus
thrombosis, stroke, critical limb ischemia, cerebral vasculitis and systemic vasculitis. Statistical analysis was performed
using R (v3.4.1).
Results: Cardiac and vascular involvement was present in 47% of the cohort. Previous studies have reported
prevalence of 5%—50%. Demographic features of those with cardiac/vascular involvement did not differ from the
overall cohort. Echocardiographic data were available for 23 participants. The most common cardiac manifestations
were pericardial effusion (n = 24) and cardiac failure (n = 8), while the most common vascular manifestations were
cerebral vasculitis (n = 9), stroke (n = 7), and pulmonary embolism (n = 7). Cardiovascular manifestations were
frequently severe; one third of pericardial effusion cases required intervention, including three cases of cardiac
tamponade. Cardiac and vascular involvement conferred an increased risk of mortality (31.1% versus 10.4%).
Conclusions: Cardiac and vascular involvement were highly prevalent in this South African cohort. The mortality
rate was high, and severe manifestations were frequent. Prospective research is needed to improve knowledge of
pediatric SLE in Africa and to improve outcomes for this high-risk population.
Keywords: Lupus, Pediatric systemic lupus erythematosus, Cardiovascular disease, Echocardiography, Africa, Global
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Background
Systemic lupus erythematosus is a systemic autoimmune
disease that can manifest an array of cardiac features in-
cluding pericarditis, myocarditis, ischemic heart disease,
valvular dysfunction, as well as cerebrovascular disease,
vasculopathies, and thromboembolic disease [1–3].
Pediatric-onset SLE (pSLE) is associated with greater
mortality and a higher rate of major organ involvement
in comparison to SLE in adults [4–6]. Although cardio-
vascular outcomes are not well described in this group,
cardiovascular disease is emerging as an important cause
of mortality in individuals with pSLE [6, 7]. Cardiovascu-
lar manifestations are more frequently reported in pa-
tients of African origin, in both adult and pediatric
populations [7, 8].
Acute cardiac and vascular presentations of SLE, such
as cardiac tamponade and stroke, are associated with
significant mortality; however, a greater burden is likely
exerted by the chronic cardiovascular effects of SLE in
individuals surviving into adulthood [7, 9]. SLE patients
develop atherosclerosis earlier and more rapidly than
age- and sex-matched controls [10–12]. Early SLE onset
confers a high risk of cardiovascular disease in adult-
hood due to greater cumulative exposure to atherogenic
immune dysregulation and multisystem inflammation [9,
13]. There appears to be marked geographical variation
in the incidence of cardiac manifestations in pediatric
SLE cohorts globally [14–20]. Pericarditis is the most
commonly reported cardiac manifestation across the lit-
erature. However, its frequency appears to vary signifi-
cantly across different settings, with individual studies
reporting rates of 0.5–36.3%, depending on the setting
[7, 16–19]. A large multicenter UK cohort reported only
20% of pSLE presented with serositis (but did not distin-
guish between pleuritis and pericarditis) and less than
0.01% of patients developed cardiomyopathy, while a
population-based study of nearly 300 pSLE patients in
the USA reported a diagnosis of pericarditis in 10% of
patients [7, 16]. Studies from lower income nations
are limited to small case series and case reports. A
study of 11 children in Nigeria revealed that 36% had
pericarditis, and 45% had left ventricular dysfunction
on echocardiography [17]. A study of 33 pSLE pa-
tients in Trinidad reported that 24% had pericarditis
at presentation and 6% had a diagnosis of stroke [19].
Few published reports on cardiovascular complica-
tions of SLE in African populations exist [21–23], al-
though a recent study described high severity of lupus
myocarditis in adult SLE patients in Cape Town [24].
A similar study of 50 adult patients in Senegal re-
ported 3 cases of cardiomyopathy and 19 cases of
pericarditis, 2 with tamponade physiology [25].
Despite the increased mortality and damage accrual
described in pSLE patients, there is a paucity of data on
cardiac and vascular manifestations and outcomes in the
high-risk population of pSLE patients in South Africa.
Methods
Aims, design, and setting
This study was conducted at two large government-
funded hospitals in Cape Town, South Africa. Retro-
spective data were collected by review of medical re-
cords. The study was approved by the Human Research
Ethics Committee of the University of Cape Town. The
objectives of this study were to 1) describe the frequency
and characteristics of cardiac and vascular/thrombo-
embolic manifestations of pSLE in a multi-ethnic cohort
in South Africa and 2) compare the rates and severity of
cardiac and vascular manifestations to a large cohort of
pSLE patients in the United States of America (USA).
Participants
The Pediatric Update on Lupus in South Africa (PULSE)
cohort consists of pSLE patients who have received care
at either of two tertiary centers (Red Cross War Memor-
ial Children’s Hospital or Groote Schuur Hospital). Most
of these patients come from the Western Cape region of
South Africa, which has a pediatric population of ap-
proximately 19 million children [26, 27]. These patients
were retrospectively identified for inclusion in the cohort
by searching the digital databases of the two centers
using the South African International Classification of
Disease (ICD)-10 codes for SLE, lupus, or lupus neph-
ritis from hospital admissions or clinic visits from 1990
to 2018. In addition, on-site physicians were polled to
generate a comprehensive list of pSLE patients. The 93
patients registered in the PULSE cohort at the time of
investigation were subjected to the following inclusion
in our study: age less than 19 years old at SLE diagnosis,
who met the Systemic Lupus International Collaborating
Clinics (SLICC) [28] or the American College of
Rheumatology (ACR) classification criteria [29] for SLE,
and had evidence of one or more cardiac or vascular
manifestations of SLE. Patients in the PULSE cohort
with no evidence of cardiac or vascular disease were in-
cluded in the analysis for comparison. SLICC and ACR
criteria were retrospectively applied to each patient
using a predefined checklist during chart review, in
order to confirm the diagnosis of SLE for the purposes
of the study. Only one patient identified by ICD-10 code
was found not to meet SLICC/ACR criteria on chart re-
view and was excluded from the analysis.
Data collection
Demographic, clinical, and laboratory data were obtained
by medical record review. The subject of race in SLE re-
search is relevant, as it has been demonstrated to be an
important predictor of disease severity. This study asked
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patients or parents to identify themselves as belonging
to one of five racial groups used in population surveys in
South Africa [30]. In South Africa, the term Black refers
to people of Southern African Bantu-speaking tribal an-
cestry. The term Coloured refers to a racially heteroge-
neous group of mixed Asian, Malaysian, Indian,
Khoisan, Bantu, and European ethnicity. White refers to
people of European descent; Indian/Asian refers to
people of Indian or Asian ancestry; and Other refers to
individuals who do not identify with any one of the de-
scribed racial categories. A measure of disease activity at
initial SLE presentation was obtained using a validated
assessment tool, the Systemic Lupus Erythematosus Dis-
ease Activity Index 2000 (SLEDAI-2 K) [31]. Clinical
manifestations, laboratory results, and medical therapies
were captured at the time of diagnosis and over the
follow-up period. Autoantibodies including anti-SSA,
anti-SSB, anti-RNP, and anti-phospholipid antibodies
were not measured consistently enough across the cen-
ters to be reported. Medical therapies were recorded as
binary variables, with positivity conferred by current or
previous use of a medication.
Cardiac and vascular manifestations
Cardiac involvement was defined as evidence of one
or more of the following manifestations: cardiac fail-
ure, pericardial effusion, myocarditis, endocarditis (in-
cluding Libman-Sacks), valvular lesions, dilated or
hypertrophic cardiomyopathy, ischemic heart disease,
or cardiac arrhythmia. Vascular manifestations were
reported separately. These included ischemic or
hemorrhagic stroke, venous sinus thrombosis, pul-
monary embolism (PE), deep vein thrombosis (DVT),
critical limb ischemia, cerebral vasculitis, and systemic
vasculitis. Predefined criteria were established for the
diagnosis of each manifestation and were classified as
clinical, echocardiographic, or radiological criteria.
Clinical criteria included physician documentation in
the medical record of pericardial effusion; cardiac fail-
ure; myocarditis; stroke; critical limb ischemia; or sys-
temic vasculitis. Echocardiographic criteria included
evidence of pericardial effusion, structural cardiac re-
modelling, valvular dysfunction, valvular vegetations,
myocarditis, and dilated or hypertrophic cardiomyop-
athy. For cases of pericardial effusion requiring drain-
age due to size or causing tamponade, effusion fluid
was tested to rule out tuberculosis due to high local
prevalence of disease [32]. Radiological criteria in-
cluded computed tomography (CT) or magnetic res-
onance (MR) evidence of stroke or venous sinus
thrombosis, Doppler ultrasound evidence of DVT, CT
angiographic evidence of PE, or MR evidence of
cerebral vasculitis. Electrocardiograms could not be
reliably located and reviewed for most of the
participants, therefore we excluded electrocardio-
graphic data from the analysis.
Echocardiography
The reports of all echocardiograms performed during
the study period for a patient known to have SLE were
reviewed. All patients in the PULSE cohort (n = 93) were
cross-referenced against a repository of echocardiograms
at each facility. No echocardiogram reports were avail-
able for patients at the Groote Schuur Hospital site prior
to 2014. Both transthoracic and transoesophageal echo-
cardiograms were included. The reports for all echocar-
diograms performed for PULSE patients were reviewed
by a pediatric cardiologist. The reports were then sum-
marised as binary variables, with positivity conferred if
the feature was found on the echocardiogram report, to
allow common key features to be extracted and analysed
within the cohort. Cardiac failure was defined as failure
of the heart to supply blood to either systemic or pul-
monary circulation at an appropriate rate of flow, or to
receive venous return at an appropriate filling pressure,
resulting in adverse effects on the heart, the circulation,
and the patient [33]. Left ventricular systolic dysfunction
in children is defined by shortening fraction (SF) < 25%
and/or an ejection fraction (EF) < 55% [33, 34, 35]. EF is
classified as normal (EF ≥ 55%), slightly reduced (EF 41–
55%), moderately reduced (EF 31–40%), and markedly
reduced (EF ≤ 30%) [36]. Pericardial effusion is identified
in echocardiography as an echolucent space adjacent to
the cardiac structures. The major echocardiographic
signs that corroborate the clinical diagnosis of cardiac
tamponade are systolic collapse of the right atrium and
diastolic collapse of the right ventricle, dilatation of the
inferior vena cava without respiratory change, and pres-
ence of respiratory change in flow velocities through the
cardiac valves [37].
Outcome measures
Outcomes that were measured included mortality and
loss to follow up. All patients enrolled in the PULSE
cohort who met inclusion criteria were accounted for
during the analysis, in one of three categories: actively
following up; deceased; or lost to follow-up. The first
category encompassed patients actively following up
with a healthcare provider, in either the adult or
pediatric service. The status of these patients was
confirmed using two electronic databases used to
manage clinical and attendance information, and la-
boratory results. Patients were recorded as “actively
following up” if they had been admitted, attended an
outpatient appointment, or had new laboratory results
logged between 1 January 2018 and 31 December
2018. The medical records systems at each center
were used to document mortality. Patients were
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recorded as “lost to follow up” if there was no death
documentation, and no record of admission, clinic at-
tendance, or new laboratory results being logged
within the previous year.
Comparison data
Data from a large, recently published, population-
based study of cardiovascular disease in pSLE patients
in the USA were included for comparison [7]. This
study utilised a large administrative database to quan-
tify cardiac involvement in a sample of children and
adults with a new diagnosis of SLE between 2000 and
2013. A previously validated algorithm was used to
identify a total of 297 children with SLE [38, 39]. The
study reported rates of pericarditis, myocarditis, endo-
carditis, and valvular insufficiency. Secondary out-
comes included cardiac tamponade and pericardial
drainage. Cerebrovascular disease and venous
thromboembolism were reported as covariates of
interest. Patients with rheumatic heart disease and in-
fective endocarditis were excluded. This study made
use of claims-based data to make inferences about the
rate and characteristics of cardiovascular pSLE in a
US-based population. The design and context of the
study is inherently different to ours, limiting com-
parative analysis. However, it is the largest report on
cardiovascular manifestations of pSLE to date and
provides a framework within which our data can be
understood in relation to data from another setting.
For further comparison, we also included data from
several smaller single-center studies which reported
cardiac and vascular manifestations in children with
SLE [1, 4, 18, 40, 41].
Statistical analysis
We compared age of SLE diagnosis, race, presenting fea-
tures, rate of lupus nephritis (LN), laboratory features,
SLEDAI-2 K scores, treatment, and outcomes between
all patients in the study and the subgroup with cardiac/
vascular manifestations. Characterization of the patient
population was summarized using descriptive statistics
with 95% confidence intervals of means and proportions
for cohort comparison. We evaluated enrollment
SLEDAI-2 K scores of the cardiac/vascular cohort
compared to the entire South African cohort. Where ap-
propriate, Kruskall-Wallis, Pearson, chi-squared, or Fish-
er’s exact test were used to evaluate differences in both
clinical and demographic features and disease scores of
the two cohorts. All data was analysed through the stat-
istical package R version 3.4.1 [42].
Results
A total of 93 pSLE patients were included in the analysis.
Demographic features are summarized in Table 1. There
were no significant differences in the demographic fea-
tures between patients with and without cardiac/vascular
involvement. The cohort was multi-ethnic, with predom-
inantly admixed ancestry (Coloured; 65.6%) and Black
participants (25.8%), reflecting the racial demographics
of the region of the Western Cape [36].
The clinical and laboratory features at presentation are
summarised in Table 2. Presenting features were similar
between the two groups, except for rates of serositis and
positive anti-double-stranded deoxyribonucleic acid anti-
body (anti-dsDNA). Patients with cardiac/vascular in-
volvement had a trend toward greater disease activity, as
measured by the SLEDAI-2 K score. While antiphospho-
lipid antibodies (either anti-cardiolipin antibody or anti-
beta-2-glycoprotein antibody) were present at least in
one measurement in 10 of the 45 patients, they were not
measured in 20 patients with cardiac/vascular disease, or
routinely measured in patients without cardiac/vascular
disease. The large number of missing data may intro-
duce bias into this evaluation, so we excluded the data
from the table.
Thirty-one percent of the PULSE cohort demonstrated
cardiac involvement. The rates of each cardiac manifest-
ation observed in the cohort are illustrated in Table 3.
In most cases, cardiac involvement was present at the
time of SLE diagnosis (84.4%). Notably, three patients
presented with cardiac tamponade due to a large peri-
cardial effusion. Approximately one-third of cases of
pericardial effusion required pericardiocentesis, and two
patients required surgical intervention (pericardial win-
dow) due to multiple recurrences.
Vasculitic and thromboembolic manifestations were
observed in 29 % of the PULSE cohort; these data are re-
ported in Table 4. Cardiac and thromboembolic/
Table 1 Demographic features of South African pediatric SLE patients
Cardiac and vascular subgroup (n = 45) Non-cardiac/ vascular subgroup (n = 48) P-value
Mean age at diagnosis, years (SD) 11.4 (3.5) 12 (3.2) 0.460
Female % (n) 84 (38) 81 (39) 0.683
Black % (n) 33.4 (15) 18.8 (9) 0.108
Coloured (mixed ethnicity) % (n) 55.6 (25) 75 (36) 0.048
White % (n) 9 (4) 4.2 (2) 0.354
Indian % (n) 3 (1) 2 (1) 0.963
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vasculitic manifestations co-existed in 15 % of the
PULSE cohort.
Echocardiographic data were available for 23 patients,
and a total of 92 study reports were reviewed; sum-
marised in Table 5. The most common finding was peri-
cardial effusion, observed in 65% of echocardiographic
reports available for review. Of those with effusion,
nearly one third required pericardial drainage (peri-
cardiocentesis or surgery). Valvular dysfunction was
present in almost half (44%) of those patients who
underwent echocardiography. Structural cardiac remod-
elling and valve status abnormalities were frequently ob-
served. No cases of Libman-Sacks endocarditis were
observed.
The outcomes of the patients in this cohort are sum-
marised in Table 6. Mortality rate was significantly
higher in the group with cardiac/vascular involvement,
while the rate of loss to follow up was similar between
the two groups.
Discussion
This study provides the first description of the burden of
cardiac and vascular manifestations of childhood-onset
SLE patients in sub-Saharan Africa and reports distinct
cardiovascular disease severity that may be important to
guide the diagnosis and management of these patients.
Cardiac and vascular findings were reported in 31.2 and
29.0% of patients in the PULSE cohort, respectively. This
is consistent with the reported prevalence (12%—48%) of
cardiovascular involvement in pediatric studies [1, 2, 4,
7]. Variation in the prevalence reported in the literature
may be explained by single-center design, small sample
size, variation in study definitions of cardiovascular in-
volvement, and methodological differences with variable
sensitivity for the detection of subclinical manifestations.
Greater prevalence of cardiovascular involvement has
been described in African-American children with SLE;
however, this may reflect overall disease activity rather
than an independent risk factor for cardiovascular dis-
ease [7, 40]. Most cardiovascular manifestations (84.4%)
in our study were evident at initial presentation, which is
consistent with other reports [1, 7].
Pericardial effusion was the most common cardiac
manifestation in this cohort, reported at a rate (26.1%)
consistent with other pSLE studies [1, 4, 7, 18]. How-
ever, the size and impact of these effusions were quite
different than other reports. Most notably, there was a
high rate of significant effusion requiring intervention in
our cohort. Eight patients (8.6%) in the PULSE cohort
presented with hemodynamically significant pericardial
Table 2 Disease activity, clinical and laboratory features of the PULSE cohort
Cardiac and vascular group (n = 45) Non-cardiac/vascular group (n = 48) P-value
Mean SLEDAI-2 K score (SD) 21.2 (7.2) 17.4 0.11
Lupus nephritis % (n) 66.7 (30) 58 (28) 0.407
Arthritis % (n) 58 (26) 64 (31) 0.501
Serositis % (n) 44 (20) 13 (6) < 0.001
Hypertension % (n) 38 (17) 27 (13) 0.270
ANA positive % (n) 100 (45) 92 (44) 0.117
Anti-dsDNA antibody positive % (n) 93 (42) 79.2 (38) 0.048
Anti-Sm antibody positive % (n) 35.6 (16) 25 (12) 0.267
Median C3 (g/l), range 0.9–1.80 0.90 1.00 0.89
Median C4 (g/l), range 0.1–0.4 0.11 0.10 0.94
SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, ANA Antinuclear Antibodies, dsDNA Double-stranded Deoxyribose Nucleic Acid, Sm Smith,
C3 Complement 3, C4 Complement 4
Table 3 Cardiac manifestations in the PULSE cohort
PULSE cohort cardiac subgroup (n = 29) Total PULSE cohort (n = 93) Chang et al. (n = 297)
Any cardiac manifestation % (n) 100.0 (29) 31.2 (29) 17.8 (53)
Echocardiographicanalysis available % (n) 79.3 (23) 24.5 (23) NR
Pericardial effusion % (n) 82.8 (24) 25.8 (24) 10.4 (31)
Pericardiocentesis % (n) 27.6 (8) 8.6 (8) 1.5 (4)
Cardiac failure % (n) 27.6 (8) 8.6 (8) NR
Cardiomyopathy % (n) 17.2 (5) 5.4 (5) NR
Endocarditis % (n) 0 0 1.0 (3)
PULSE Pediatric Update on Lupus in South Africa, NR Not Recorded
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effusions requiring pericardiocentesis, and there were
three cases (3.2%) of cardiac tamponade (Fig. 1.) These
manifestations are infrequently reported and relevant lit-
erature reporting on tamponade or effusion requiring
intervention in pSLE patients is limited to case reports
and a single case series [41, 43–46]. However, one ana-
lysis of 297 patients with pSLE observed cardiac tam-
ponade in 0.6%, and tamponade required
pericardiocentesis in 1.5% [7]. Severe pericarditis requir-
ing intervention is an extreme presentation of pSLE, and
was much more frequently reported in the PULSE co-
hort compared to the USA cohort (8.6% versus 1.5%).
The rate is also higher than in other African cohorts. A
small Nigerian care series reported none of the pediatric
SLE patients with pericarditis having tamponade physi-
ology, and an adult study from Senegal reported 4% of
their cohort had tamponade, suggesting a resource-
limited setting is not the sole driver of this difference
[17]. This finding is consistent with a previous report of
a severe SLE phenotype in the PULSE cohort [23].
Echocardiographic data were only available for 23 par-
ticipants, although 45 presented with cardiac and/or vas-
cular disease. Our findings suggest that routine baseline
echocardiogram for all pediatric SLE patients may be of
benefit, in order to achieve early detection of cardiovas-
cular disease, although further study is needed for evi-
dence based guidelines for cardiac screening in this
setting.
In the subgroup of patients who underwent echocardi-
ography, structural cardiac remodelling was highly
prevalent, with left and right ventricular hypertrophy be-
ing reported in 39 and 13% of cases, respectively. A pre-
viously described Taiwanese cohort of 157 patients with
pSLE reported structural cardiac remodelling in 17.8% of
patients [1]. Valvular dysfunction was reported in 10.8%
of the PULSE cohort. This rate is comparable with other
studies, which report valve disease at a rate of 6.5 to
19.7% [1, 7, 18, 41]. No valvular vegetations were docu-
mented, consistent with the low frequency of this disease
reported in the pediatric population [1, 7]. Thirteen
Table 4 Vascular manifestations in the PULSE cohort
PULSE cohort vascular subgroup (n = 27) Total PULSE cohort (n = 93) Chang et al. (n = 297)
Stroke % (n) 25.9 (7) 7.5 (7) 4.0 (11)
Venous thromboembolism % (n) 29.6 (8) 8.6 (8) 5.0 (15)
Deep vein thrombosis% (n) 18.5 (5) 5.4 (5) NR
Pulmonary embolism % (n) 25.9 (7) 7.5 (7) NR
Cerebral vasculitis % (n) 33.3 (9) 9.6 (9) NR
Major organ vasculitis other than CNS % (n) 7.4 (2) 2.1 (2) NR
PULSE Pediatric Update on Lupus in South Africa, NR Not Recorded, CNS Central Nervous System
Table 5 Echocardiographic features in the PULSE cohort compared to pSLE patients in the USA
PULSE subgroup who underwent echocardiography (n = 23) Total cohort (n = 93) Chang et al. (n = 297)
Reduced LVEF % (n) 13 (3) 3.2 (3) NR
Markedly reduced LVEF % 2.2 (1) 1 (1) NR
Left ventricular hypertrophy % (n) 39 (9) 9.8 (9) NR
Right ventricular hypertrophy % (n) 13 (3) 3.2 (3) NR
Right ventricular dilation % (n) 9 (2) 2.1 (2) NR
Cardiomyopathy % (n) 4 (1) 1.1 (1) NR
Effusion % (n) 65 (15) 16.1 (15) 10.4 (31)
Tamponade 6.7 (3) 3.2 (3) 0.7 (2)
Effusion requiring intervention % (n) 30 (7) 7.5 (7) 1.5 (4)
Valvular dysfunction % (n) 44 (10) 10.8 (10) 9.1 (27)
Aortic regurgitation % (n) 4 (1) 1.1 (1) NR
Pulmonary regurgitation % (n) 4 (1) 1.1 (1) NR
Tricuspid regurgitation % (n) 4 (1) 1.1 (1) NR
Mitral regurgitation % (n) 4 (1) 1.1 (1) NR
Multiple valves % (n) 26 (6) 6.4 (6) NR
Severe valvular dysfunction % (n) 26 (6) 6.4 (6) NR
NR Not Recorded
Harrison et al. Pediatric Rheumatology           (2019) 17:76 Page 6 of 10
percent of patients undergoing echocardiography in this
cohort had reduced left ventricular ejection fraction
(LVEF) (Fig. 2), suggesting that the rate of cardiac dys-
function in the PULSE cohort is higher than clinically
detected. Pediatric SLE patients have been reported to
have lower LVEF than healthy age-matched controls that
represents cardiac dysfunction even when LVEF is
within normal range; therefore, an abnormal LVEF is a
concerning finding in our cohort [47]. Studies in both
adults and children with SLE demonstrate a high preva-
lence of subclinical cardiac disease, leading many to mo-
tivate for routine use of echocardiography [2, 48–50]. As
children with SLE have a higher cumulative risk of dam-
age accrual, and risk factors for cardiac involvement in
these patients remain unknown, routine echocardiogram
may be of greater benefit in the pediatric population, al-
though formal guidelines regarding the frequency of
monitoring are lacking.
Cerebrovascular disease presented in 8.6% of the
PULSE cohort, consistent with the rate reported in the
literature (2.2 to 12%) [51–53]. This included six cases
of cerebral infarction, one case of hemorrhagic stroke,
and one case of sinus venous thrombosis. Strikingly,
cerebral vasculitis was reported in 9.7% of the PULSE
cohort. This rate is high, as cerebral vasculitis is consid-
ered a rare entity in both children and adults with SLE
[54–56]. Our study was not designed to determine the
cause of this high rate in our cohort, but further re-
search is required to investigate and explain this inter-
esting finding.
Finally, the high incidence and severity of both cardiac
and vascular disease in this cohort is associated with
poor outcomes. Patients with cardiac and/or vascular
manifestations had greater mortality compared to those
without such involvement (31.1% vs. 10.4%, p-value =
0.013).
This study provides initial insights into the burden of
cardiac, vascular and thromboembolic disease complica-
tions of lupus in a multi-ethnic cohort of children in
South Africa. Cardiac and vascular manifestations were
common and often severe in the PULSE cohort. In our
cohort, echocardiographic data were only available for
51% of patients with cardiac symptoms. Cardiac or vas-
cular involvement was associated with markedly in-
creased mortality compared to peers in the same cohort.
This suggests that echocardiography should be per-
formed more consistently in pSLE patients in South
Africa. In our opinion, clinicians caring for children with
SLE in South Africa should consider performing baseline
echocardiography within a year of SLE diagnosis.
Additionally, parents and patients should be routinely
educated about the recognition and importance of car-
diovascular symptoms in SLE. Our study design was not
able to identify factors contributing to the high









Deceased % (n) 37.9 (11) 29.6 (8) 10.4 (5) 20.4 (19)
Lost to follow up % (n) 13.7 (4) 7.4 (2) 14.5 (7) 11.8 (11)
Fig. 1 Echocardiogram showing a large circumferential pericardial effusion with diastolic collapse
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prevalence and severity of cardiovascular manifestations
observed in this cohort. In our setting, environmental
factors such as poverty, barriers to healthcare, and diag-
nostic delays may contribute [57, 58]. Equally, our co-
hort has a high number of patients of African ancestry,
and it is possible that genetic factors may play a role in
explaining the severe cardiovascular disease observed in
this population. The long-term burden of cardiovascular
effects of pSLE remains undetermined in the PULSE
cohort.
The PULSE cohort is the largest group of pSLE pa-
tients on the African continent. However, the relatively
small size of the cohort limited statistical power. Partici-
pants were recruited from two tertiary medical centers
within one city in the Western Cape province of South
Africa. Ethnic composition and health systems in this re-
gion differ considerably from the rest of the continent,
limiting the generalisability of these findings to other
settings and populations. The study was further limited
by a retrospective design, the documented medical rec-
ord and the availability of laboratory, echocardiographic
and radiological data. Echocardiogram reports at one of
the study sites were not reliably stored prior to 2014,
limiting the number of participants with echocardio-
graphic data. Electrocardiograms could not be reliably
traced for most of the participants, leading the re-
searchers to exclude electrocardiographic data from the
analysis. Data for the USA-based comparison cohort was
collected between 2000 and 2013, whereas the PULSE
cohort collected data between 2005 and 2018. The rate
of cardiac disease in children may have differed during
these periods.
A large, prospective, multi-site cohort is needed to de-
termine the burden of pSLE in sub-Saharan Africa, to
inform practice and improve outcomes for these pa-
tients. Translational research is required to investigate
genetic markers that confer an increased risk of severe
disease in African patients. Prospective studies using
echocardiography and non-invasive measures of endo-
thelial function are needed to determine the burden and
characteristics of subclinical cardiovascular disease in
this at-risk population.
Conclusions
This study provides initial insights into the burden of
cardiac and vascular manifestations of lupus in a multi-
ethnic cohort of children in South Africa. Cardiac and
vascular manifestations were common and often severe
in the PULSE cohort. Prospective studies, long term fol-
low up, and translational research are needed to under-
stand the drivers and long-term implications of these
findings.
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